BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 18243505)

  • 1. Serum markers for prostate cancer: a rational approach to the literature.
    Steuber T; O'Brien MF; Lilja H
    Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New circulating biomarkers for prostate cancer.
    Bensalah K; Lotan Y; Karam JA; Shariat SF
    Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.
    Brown DA; Stephan C; Ward RL; Law M; Hunter M; Bauskin AR; Amin J; Jung K; Diamandis EP; Hampton GM; Russell PJ; Giles GG; Breit SN
    Clin Cancer Res; 2006 Jan; 12(1):89-96. PubMed ID: 16397029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for prostate cancer detection.
    Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
    J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.
    Schröder FH; Carter HB; Wolters T; van den Bergh RC; Gosselaar C; Bangma CH; Roobol MJ
    Eur Urol; 2008 Mar; 53(3):468-77. PubMed ID: 17997011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New markers and multivariate models for prostate cancer detection.
    Stephan C; Rittenhouse H; Cammann H; Lein M; Schrader M; Deger S; Miller K; Jung K
    Anticancer Res; 2009 Jul; 29(7):2589-600. PubMed ID: 19596933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro PSA : a "pro cancer" form of PSA?
    Peyromaure M; Fulla Y; Debré B; Dinh-Xuan AT
    Med Hypotheses; 2005; 64(1):92-5. PubMed ID: 15533620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
    Shariat SF; Karam JA; Margulis V; Karakiewicz PI
    BJU Int; 2008 Mar; 101(6):675-83. PubMed ID: 17941930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are multiple markers the future of prostate cancer diagnostics?
    Mikolajczyk SD; Song Y; Wong JR; Matson RS; Rittenhouse HG
    Clin Biochem; 2004 Jul; 37(7):519-28. PubMed ID: 15234233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
    Fradet Y
    Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood biomarkers for prostate cancer detection and prognosis.
    Shariat SF; Karam JA; Roehrborn CG
    Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen in clinical practice.
    Loeb S; Catalona WJ
    Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
    Lin DW
    Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    Crawford ED; Abrahamsson PA
    Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.